Navigation Links
SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193

NEW YORK--(BUSINESS WIRE)--May 15, 2007 - SIGA Technologies, Inc. (NASDAQ: SIGA) announced today the successful results of a proof of concept guinea pig trial of its lead Lassa fever virus drug, ST-193.

This study was conducted under Biosafety Level 4 conditions at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) by Dr. Kathleen Cashman under the supervision of Dr. Mary Guttieri, who has been working on various hemorrhagic fever viruses at USAMRIID for over 12 years. Strain 13 guinea pigs were challenged with a lethal dose of Lassa virus and treated with ST-193 once a day for 14 days. Administration with ST-193 resulted in significant reduction in mortality at the two doses tested, 80 mg/kg and 25 mg/kg (71% of the animals survived at the low dose), whereas all of the control animals and those treated with ribavirin succumbed to the disease within 20 days of the challenge. The disease course in these guinea pigs recapitulates what is seen in human Lassa fever infections, and SIGA expects that this model is one of the two animal models that will be required to fulfill the U.S. Food and Drug Administration's "Animal Efficacy Rule."

"This is a tremendous milestone for our research group," said Dr. Dennis E. Hruby, SIGA's Chief Scientific Officer. "This study should provide the basis for advancing this lead candidate into IND-enabling activities in the near future."

Lassa virus, considered a hemorrhagic fever virus due to some of its prominent symptoms, is one type of arenavirus. Arenaviruses are potential biological weapons agents due to their ease of dissemination, person-to-person transmissibility, and potential to cause widespread illness and death. Creating and deploying antiviral drugs targeting arenaviruses will enhance national and global security by acting as a significant deterrent and defense against the use of arenaviruses as bioterror weapons. Six separate arenav
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Senate Passes Drug-Safety Reforms to Prevent Future Vioxx-type Disasters; House Urged to Act on Strong Drug Safety Bill
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
5. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
6. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
7. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
8. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
9. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
10. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
11. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: SIGA Passes First Hurdle with Lassa Fever Antiviral
(Date:5/22/2015)... Electrophysiologist Kevin Makati, M.D. with St. ... Boston, MA to speak about ... Society conference. These scientific sessions drew more than ... people and technology that propel their specialty forward. ... invasive cardiac operation that combines the expertise of ...
(Date:5/22/2015)...  The U.S. Food and Drug Administration,s (FDA) ... biosimilar product approved in the United ... the contract manufacturing organization (CMO) industry, according to ... to the production of small-molecular drugs and lacks ... healthcare market research publisher,s report, Biopharmaceutical and ...
(Date:5/22/2015)... , May 22, 2015 According ... Market by Product (Consumables, Instruments, Services), by Test Type ... Chromatography, Flow Cytometry), by End Users - Global Forecast ... Market is expected to reach $736.85 Million by 2020 ... of 10.25%. Browse 71 market data ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4
... research at SRI International, scientists evaluating new drug targets against ... that could rapidly eliminate infections and potentially shorten treatment time. ... B, found in bacteria that cause TB infections. ... A and gyrase B. Although gyrase A is often the ...
... 29, 2011   Acuo Technologies ® ... for intelligent medical image lifecycle management and data ... has selected the Universal Clinical Platform (UCP3) ... UCP3 will replace Fairview,s existing PACS archives while ...
Cached Medicine Technology:SRI Researchers Validate Preclinical Effectiveness of Tuberculosis Drug Target that Could Shorten Treatment Time 2Acuo Technologies Announces Vendor Neutral Archiving Contract with Fairview Health Services 2Acuo Technologies Announces Vendor Neutral Archiving Contract with Fairview Health Services 3
(Date:5/22/2015)... May 22, 2015 The world ... and capacity are intersecting to create new opportunities ... the opening speaker at WesternU's 34th annual Commencement ... Gov. Gavin Newsom, a former San Francisco mayor ... speaker at the graduation ceremony for WesternU's colleges ...
(Date:5/22/2015)... Liverpool, OH (PRWEB) May 22, 2015 ... announced that Kyle Johnson, the health system’s Chief Financial ... other interests. Johnson has served as the company CFO ... Wesley West will be joining the health system as ... on an interim basis, while the Board of Trustees ...
(Date:5/22/2015)... Combination therapy, or polytherapy, will ... obstructive pulmonary disorder (COPD) as the dominant companies ... as well as Germany’s Boehringer Ingelheim compete with ... will market payers, clinicians and patients be disposed ... completely new ones? , In spite of recently ...
(Date:5/22/2015)... 2015 Carnegie Science Center ... a new partnership to develop BodyTech, a dynamic, three-pronged ... initiative includes a new exhibit at the Science Center ... and a new traveling science show, Anatomy Adventure, which ... , Designed to explore a wide range of ...
(Date:5/22/2015)... Power Systems is proud to announce the ... season. Drobeck is in his second year of racing in ... the Missoula Fire Department in Missoula, MT. He entered the ... During his career, he has had 15 1st Place finishes. ... 10 finishes in all seven of his 2014 races, including ...
Breaking Medicine News(10 mins):Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4
... Scientists at the ,University of North Carolina at Chapel ... plays a central role in the formation of new blood ... new blood vessel formation, or angiogenesis, is seriously impaired without ... 2011 in the journal Blood , was led by ...
... prevention trial that has been evaluating two antiretroviral (ARV)-based approaches ... daily use of one of two different ARV tablets or ... The decision to discontinue use of the gel, which contains ... study data concluded tenofovir gel was not effective in preventing ...
... -- Patients hospitalized for autoimmune disorders, like rheumatoid arthritis ... life-threatening pulmonary embolism, a clot in a main artery of ... 25 in The Lancet , researchers warned that steps ... to the hospital for autoimmune diseases. , , In conducting ...
... CHICAGO By combining conventional medical imaging with some ... blockbusters, researchers are offering new hope to victims of ... human face transplantation, led by Darren M. Smith, M.D., ... Center (UPMC), were presented today at the annual meeting ...
... News) -- Racism is similar to trauma in how ... the United States, a new analysis finds. An ... 18,000 black adults concluded that there are common responses ... that is expressed as physical pain), interpersonal sensitivity and ...
... should be able to choose where they give birth, concludes ... first-time mums who opt for a home birth are at ... low in all birth settings. The researchers say their ... pregnancies a choice of birth setting" and will enable women ...
Cached Medicine News:Health News:Cell molecule identified as central player in the formation of new blood vessels 2Health News:Cell molecule identified as central player in the formation of new blood vessels 3Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 2Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 3Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 4Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 5Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 6Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 7Health News:Autoimmune Woes May Raise Risk for Lung Clots 2Health News:Integrated 3-D imaging facilitates human face transplantation 2Health News:Integrated 3-D imaging facilitates human face transplantation 3Health News:Pregnant women at low risk of complications can safely be offered a choice of where to give birth 2
Stainless steel bone clamp....
Lewin Bone Forceps, serrated and slightly curved. To hold, stabilize, rotate, reduce and,compress bone....
Straight double action bone cutting rongeur....
Beuse Zygomatic Arch Awl with slightly curved tip....
Medicine Products: